Skip to main content

Investors

Ulisse Biomed Group is an integrated biotech group with proprietary technologies, developing diagnostic solutions with a focus on public health, distributed diagnostics and molecular innovation.

About Us

We are technology leaders in distribuited and connected diagnostics


Investors

The Ulysses Biomed Group is an integrated biotech group with proprietary technologies, developing diagnostic solutions with a focus on public health, distributed diagnostics and molecular innovation.


Concluded extraordinary transactions

Reserved Capital Increase


27 December 2024
ILLUSTRATIVE REPORT OF THE BOARD OF DIRECTORS PREPARED PURSUANT TO ARTICLE 2441, CO. 6, ITALIAN CIVIL CODE, ON THE EXERCISE OF THE DELEGATION OF POWERS PURSUANT TO ARTICLE 2443, CO. 5, C.C. CONCERNING A RESERVED CAPITAL INCREASE
Download
OPINION OF THE BOARD OF STATUTORY AUDITORS OF THE COMPANY ULISSE BIOMED S.P.A. ON THE APPROPRIATENESS OF THE ISSUE PRICE OF NEW SHARES (ART. 2441, PARAGRAPH 6, CIVIL CODE)
Download
27 November 2024
ILLUSTRATIVE REPORT OF THE BOARD OF DIRECTORS PREPARED PURSUANT TO ARTICLE 2441, CO. 6, ITALIAN CIVIL CODE, ON THE EXERCISE OF THE DELEGATION OF POWERS PURSUANT TO ARTICLE 2443, CO. 5, C.C. CONCERNING A RESERVED CAPITAL INCREASE
Download
OPINION OF THE BOARD OF STATUTORY AUDITORS OF THE COMPANY ULISSE BIOMED S.P.A. ON THE APPROPRIATENESS OF THE ISSUE PRICE OF NEW SHARES (ART. 2441, PARAGRAPH 6, CIVIL CODE)
Download
25 Setttembre 2024
ILLUSTRATIVE REPORT OF THE BOARD OF DIRECTORS PREPARED PURSUANT TO ARTICLE 2441, CO. 6, ITALIAN CIVIL CODE, ON THE EXERCISE OF THE DELEGATION OF POWERS PURSUANT TO ARTICLE 2443, CO. 5, C.C. CONCERNING A RESERVED CAPITAL INCREASE
Download
OPINION OF THE BOARD OF STATUTORY AUDITORS OF THE COMPANY ULISSE BIOMED S.P.A. ON THE APPROPRIATENESS OF THE ISSUE PRICE OF NEW SHARES (ART. 2441, PARAGRAPH 6, CIVIL CODE)
Download

Capital increase under option


Application form for the option offer of ordinary shares of Ulisse Biomed S.p.A. (facsimile)
Download
Notice of filing of option offer pursuant to Article 2441(2) of the Civil Code
Download
KID for option rights with ISIN code IT0005576183
Download
Press release of 15 December 2023 - The Board of Directors partially exercises its proxy to increase the share capital under option
Download
Press release of 21 December 2023 - Shareholders' meeting approves reverse take-over transaction and capital increase in kind to service it
Download
Press release of 21 December 2023 - Deed of transfer of the entire shareholding in Hyris Limited in favour of Ulysses Biomed signed. Fulfilment of the condition to which the capital increase under option was subject. Co-optation of Stefano Lo Priore to replace resigning Chairman Saverio Scelzo
Download
Press release of 22 December 2023 - Publication of the KID for option rights with ISIN code IT0005576183
Download
Press release of 23 January 2024 - Publication of the KID for the unexercised option rights with ISIN code IT0005576217
Download
KID for unexercised option rights with ISIN code IT0005576217
Download